Cumulative Serum Endothelin-1 and Endothelin-3 Level Predicts 1-year Adverse Cardiac Events after ST-Elevation Acute...

Area of Science:

• Cardiology
• Biochemistry
• Clinical Research

Background:

• Endothelin-1 (ET-1) and endothelin-3 (ET-3) contribute to vasoconstriction, potentially worsening myocardial infarction severity.
• Elevated ET-1 and ET-3 levels during acute myocardial infarction (AMI) may impact patient outcomes.

Purpose of the Study:

• To investigate the association between cumulative endothelin-1 (ET-1) and endothelin-3 (ET-3) levels and major adverse cardiac events (MACE) one year after AMI.
• To identify ET-1 and ET-3 as potential predictors of MACE in ST-elevation myocardial infarction (STEMI) patients.

Main Methods:

• Retrospective cohort study of 81 ST-elevation acute myocardial infarction (STEMI) patients.
• Serum ET-1 and ET-3 levels measured at admission using ELISA assay.
• One-year follow-up to identify MACE; multivariate logistic regression used for analysis.

Main Results:

• Major adverse cardiac events (MACE) occurred in 29.3% of subjects within one year.
• A cumulative ET-1 and ET-3 level exceeding 17.0 ng/mL was independently associated with 1-year MACE (aOR = 5.34, p = 0.017).
• Higher cumulative serum ET-1 and ET-3 levels at admission predict 1-year MACE after STEMI.

Conclusions:

• Cumulative serum ET-1 and ET-3 levels are significant predictors of 1-year MACE in STEMI patients.
• These endothelin levels may serve as a biomarker for risk stratification following AMI.
• Further research could explore therapeutic targeting of the endothelin system in AMI management.